I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Northern Technologies International Corporation Reports the Resignation of Dr. Donald A. Kubik
Date : 08/30/2010 @ 12:02PM
Source : GlobeNewswire Inc.
Stock : Northern Technologies International Corporation (NTIC)
Quote : 9.3999 -0.5901 (-5.91%) @ 3:50PM
Northern Technologies International (MM) (NASDAQ:NTIC)
Northern Technologies International Corporation (Nasdaq:NTIC) today reported the resignation of Dr. Donald A. Kubik (age 70) as Director and as Vice-Chairman of the Board of Directors due to health concerns. Upon receiving this news, the Board of Directors invited Dr. Kubik to continue to serve the Company as both a Director Emeritus as well as a consultant to various R&D projects.
G. Patrick Lynch, President and Chief Executive Officer of NTIC, said, "Don Kubik has made immeasurable contributions to the Company during his 32 year tenure with the company, both as a Director and an employee. We are deeply grateful for all he has done for NTIC, and are saddened by the circumstances that have caused Don to step down as a Director. All concerned, however, know that Don will always take action in the best interests of this Company which he helped to build."
The NTIC Nominating Committee is continuously searching for highly qualified Directors, but there are neither immediate plans nor regulatory requirements to replace the vacancy Dr. Kubik has created.
About Northern Technologies International Corporation
Northern Technologies International Corporation develops and markets proprietary environmentally beneficial products and technical services either directly or via a network of joint ventures and independent distributors in over 50 countries. NTIC's primary business is corrosion prevention. NTIC has been selling its proprietary ZERUST® and EXCOR® rust and corrosion inhibiting products and services to the automotive, electronics, electrical, mechanical, military and retail consumer markets, for over 30 years. NTIC also offers worldwide on-site technical consulting for rust and corrosion issues. NTIC's technical service consultants work directly with the end users of NTIC's products to analyze their specific needs and develop systems to meet their technical requirements. In addition, NTIC markets proprietary bio-plastic technologies under the Natur- Tec® brand. Finally, NTIC's Polymer Energy® joint venture manufactures and sells advance waste plastic to fuel conversion machines. and is in various stages of development with respect to several other emerging businesses.
The Northern Technologies International Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5481
Forward-Looking Statements
Statements contained in this press release
that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such statements include our expectations regarding the future performance of our new businesses and other statements that can be identified by words such as "expect," "intend," "continue," "anticipate," "estimate," "potential," "will," "would," or words of similar meaning and any other statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of NTIC's management and are inherently subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties include, but are not limited to, in no particular order: NTIC's dependence on the success of its joint ventures and technical fees and dividend distributions that NTIC receives from them; NTIC's relationships with its joint ventures and its ability to maintain those relationships; risks associated with NTIC's international operations; exposure to fluctuations in foreign currency exchange rates; the current financial crises affecting the U.S. and worldwide banking system and financial markets; contraction of the U.S. and worldwide economies, including in particular the U.S. automotive industry; the level of growth in NTIC's markets; NTIC's investments in research and development efforts; acceptance of existing and new products; increased competition; the success of NTIC's new businesses; the costs and effects of complying with changes in tax, fiscal, government and other regulatory policies, including rules relating to environmental, health and safety matters, NTIC's reliance on its intellectual property rights and the absence of infringement of the intellectual property rights of others, the ability of NTIC's lender to declare outstanding indebtedness immediately due and payable and current and potential litigation. More detailed information on these and additional factors which could affect NTIC's operating and financial results is described in the company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. NTIC urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. Additionally, NTIC undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: Northern Technologies International Corporation
Investor and Media Contacts:
Matthew Wolsfeld, CFO
(763) 225-6600
Lighting Science Group Begins Trading Today on the OTCBB
Date : 08/30/2010 @ 8:52AM
Lighting Science Group Corporation Common Stock (OTCBB:LSCG)
Lighting Science Group Corporation (OTC Bulletin Board: LSCG), a leading U.S. maker of LED lighting, announced today that its common stock will commence trading on the OTC Bulletin Board (OTCBB) under the ticker symbol "LSCG" today, August 30, 2010.
"Having our shares traded on the OTC Bulletin Board is an important part of our strategy to increase the Company's liquidity and transparency with retail and institutional investors," said Zach Gibler, Chief Executive Officer, Lighting Science Group. "The listing is one in a series of recent actions the Company has taken to build value for shareholders, including significantly reducing debt and strengthening our board of directors. We look forward to providing updates on our line of products, distribution and manufacturing agreements as we continue our growth and expansion."
About Lighting Science
Lighting Science Group Corporation (OTCBB: LSCG) designs, develops, manufactures and markets LED lighting solutions that are environmentally friendlier and more energy efficient than traditional lighting products. Lighting Science Group offers retrofit LED lamps in form factors that match the form factor of traditional lamps or bulbs and LED luminaires for a range of applications including public and private infrastructure for both indoor and outdoor applications. Lighting Science Group Design Works business unit designs, develops and manufactures custom LED lighting solutions for architectural and artistic projects. Lighting Science Group is headquartered in Satellite Beach, Florida; Lighting Science Group Design Works business unit is based in Rancho Cordova, California; the Company's European operations are based in Goes, The Netherlands; and, the Company has a sales office in Sydney, Australia. Lighting Science Group has over 200 workers in its Satellite Beach, Florida manufacturing facility that build lighting products from domestic and imported parts. Lighting Science Group is a Pegasus Capital Advisors portfolio company. More information about Lighting Science Group is available at www.lsgc.com.
Forward Looking Statements Certain statements in this press release may constitute "forward-looking statements" made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The statements include, but are not limited to statements regarding the performance of LSG and the performance of LSG's products using terminology such as "revolutionary," "significant," "substantial," "development," "well positioned," "leading," "breakthrough," "advance," "success," "will," "should," "expected," "best in class," "unparalleled," "would," "could," "expect," "intend," "plan," "anticipate," "believe," "potential," "opportunity," "greater," "preparing," "excellent" or "extensive." Such statements reflect the current view of LSG with respect to future events and are subject to certain risks, uncertainties and assumptions. Known and unknown risks, uncertainties and other factors could cause actual results to differ materially from those contemplated by the statements. In evaluating these statements, you should specifically consider various factors that may cause our actual results to differ materially from any forward-looking statements. Readers should carefully review the risk factors detailed under "Risk Factors" in our Form 10-K's, Form 10-Q's and other Securities and Exchange Commission filings.
SOURCE Lighting Science Group Corporation
Keep your eye on APNT one of my no-brainer picks that has held up well this summer. Not your average penny stock. It moves on very small volume. If they strike a deal with Samsung to use their nanotube tech patents then it could be hard to catch if your not already holding IMHO.
Latest shareholders letter says it much better than I could, but here are a couple highlights.
http://www.appliednanotech.net/investors/shareholder_comm_07_10.php
At the macro financial level, we continue to be heavily focused on reaching profitability for 2010. As mentioned in our recent press release, we received the final up-front portion of the license payment from Ishihara for our conductive copper inks and pastes. This will bring our revenue for the first six months of 2010 to close to $3 million. We are still in the process of closing our books as of June 30, 2010, but we will be profitable for the 2nd quarter and we expect to be profitable at the income from operations level for the entire six month year to date period. Some of the non-cash costs associated with our financing from earlier in the year likely will prevent us from reaching breakeven at the net income level for the total six month period ended June 30, 2010.
We have a strong cash position – over $2.1 million as of June 30, 2010, which is the highest cash level we have had at a quarterly filing date since March 2008. This cash, when combined with our known revenue sources will enable us to operate well into the 2nd quarter of 2011 - this before considering many of the fantastic opportunities in front of us. In addition, we have a strong revenue backlog and are well on our way to having enough revenue in the pipeline to reach the $6.0 to $6.5 million of revenue that we need to be profitable for the year. While not totally there yet, we still expect sufficient revenue in 2010 to reach at least breakeven. Of course, our goal is not simply to breakeven, but to be profitable. We currently are pursuing numerous opportunities that could put us well over the top and result in much more than nominal profits in 2010. Dr. Yaniv, I, and the rest of the team, are more excited with the size and breadth of opportunities in front us than we ever have been before.
Amen... A tale of two JBI's. It was the best of times, it was the worst of times...
AKA - The short kindergarten version of why we are where we are today.
Only time will tell if JB can produce on the claims made and take JBII stock to new heights or the P2O process proves not to be a viable business model and JBII will become valued based on the other businesses.
At this moment in time there is a good reason that the stock is priced where it is right now. It looks to me like JB was feeling like superman before the AGM and could spout out what ever thought came into his head on FB (I do not think it is fair to call them promises but more like current thoughts and plans that would change as the situation changed). He was basking in the spotlight and if he had not encountered the oxygen sensor problem and the off-gas problem, then the stock probably would have held and continued upward as long as he had received the permit and had the media event in a timely fashion. Then for the icing on the downward spiral cake, we have the E status then losing the OTCBB status along with the large number of shares becoming unrestricted. I would bet that JB is also taking the good advice from his lawyers and going silent on FB as they are now communicating though professional channels like a big board stock. This stock has been punished for talking of NASDAQ and then being delisted even though their books are now prepared to uplist to a higher exchange once they get the stock price back up into qualifying range.
We are all here to make money and you cannot argue that dropping from over $7 to under $.80 so far this year is bad for long shareholders (except maybe for those of us who were able to average down). JBI as a company has grown up (with a top firm auditing). JB appears to be also growing up (ceasing FB musings).
I think most of us can agree that JB must know right now if he has built a P2O processor that is cheaper to operate, cheaper to build and also more efficient than any current competitor. So the key questions to me right now are:
1) If JB does not believe that he has "the goods", would he be using the capital resources to build additional processors and updating the blending site while forgoing his CEO pay until after after a permit is obtained? Don't you think he would be saving cash for another venture or to line his pocket, if his P20 did not work better that competitors?
2) After all the new cautionary statements with the new audited financials, would JB stick his neck out on a limb by basically stating that the company has enough funds to get P2O into production? This is very important because the price of JBII stock ($.10 or $100) will not have any impact on the companies operations UNTIL they need to raise additional funds. If the permit happens and a reputable independent 3rd party can give a production report that will verify the efficiency claims and cost effectiveness of the system, then the media exposure should put JBII stock back to new heights and beyond as investors see the long term value IMHO.
3) Will there be other problems and delays after the permit and fuel is being produced? Yes, but with income coming in from fuel sales they should not have the impact that the stack test and permit have had on the stock price IMHO.
Breaking below the dollar was not good. I will be watching for the bottom as I do think this is in a turn-around mode but not look to catch a falling knife here.
If the general markets don't tank, then I think this is a really good entry point. I like the stock long-term too, but I believe it has to make the successful transition from lab to human before it will run and hold, IMHO.
Interesting. So it is your opinion that "feeling heat" is trouble for a competing company but "feeling nauseous" and "vomiting" will not become a similar problem for LNGT? I personally think the argument should really be which non-lethal would you rather be subdued by if you need to be contained by law enforcement: Gun with rubber bullets, Taser, Dazer or Heat but in our culture the lawyers are more likely to make the decision and rule them all out, eventually.
Thank you for the person mark and welcome to the Mesoblast board.
A tale of two JBI's. It was the best of times, it was the worst of times...
AKA - The short kindergarten version of why we are where we are today.
Only time will tell if JB can produce on the claims made and take JBII stock to new heights or the P2O process proves not to be a viable business model and JBII will become valued based on the other businesses.
At this moment in time there is a good reason that the stock is priced where it is right now. It looks to me like JB was feeling like superman before the AGM and could spout out what ever thought came into his head on FB (I do not think it is fair to call them promises but more like current thoughts and plans that would change as the situation changed). He was basking in the spotlight and if he had not encountered the oxygen sensor problem and the off-gas problem, then the stock probably would have held and continued upward as long as he had received the permit and had the media event in a timely fashion. Then for the icing on the downward spiral cake, we have the E status then losing the OTCBB status along with the large number of shares becoming unrestricted. I would bet that JB is also taking the good advice from his lawyers and going silent on FB as they are now communicating though professional channels like a big board stock. This stock has been punished for talking of NASDAQ and then being delisted even though their books are now prepared to uplist to a higher exchange once they get the stock price back up into qualifying range.
We are all here to make money and you cannot argue that dropping from over $7 to under $.80 so far this year is bad for long shareholders (except maybe for those of us who were able to average down). JBI as a company has grown up (with a top firm auditing). JB appears to be also growing up (ceasing FB musings).
I think most of us can agree that JB must know right now if he has built a P2O processor that is cheaper to operate, cheaper to build and also more efficient than any current competitor. So the key questions to me right now are:
1) If JB does not believe that he has "the goods", would he be using the capital resources to build additional processors and updating the blending site while forgoing his CEO pay until after after a permit is obtained? Don't you think he would be saving cash for another venture or to line his pocket, if his P20 did not work better that competitors?
2) After all the new cautionary statements with the new audited financials, would JB stick his neck out on a limb by basically stating that the company has enough funds to get P2O into production? This is very important because the price of JBII stock ($.10 or $100) will not have any impact on the companies operations UNTIL they need to raise additional funds. If the permit happens and a reputable independent 3rd party can give a production report that will verify the efficiency claims and cost effectiveness of the system, then the media exposure should put JBII stock back to new heights and beyond as investors see the long term value IMHO.
3) Will there be other problems and delays after the permit and fuel is being produced? Yes, but with income coming in from fuel sales they will not have the impact that the stack test and permit have had on the stock price IMHO.
If you are looking for a really wild guess, I have one (the company is welcome to correct me at any time by telling shareholders what the current status is). Could someone who wanted to support "the Walters" without going through the normal reporting channels just buy stock here? There is no bid and we know who gets all the money here, right? I mean, if they can get a bid then it is just a normal stock that can trade up and down but without a bid isn't it more like personal piggy bank? Just interesting questions, not accusations.
I do believe we have found a diamond in the rough here. Time will tell.
ADR is the key difference. Some ADR's trade on the big boards and If Mesoblast / Angioblast continues to make good progress in the US and abroad, then maybe they will uplist our ADR for easier access to USA capital markets.
Me Too :) I feel like we are the only two people in the USA that are aware of this stock. After the special meeting, I think things will really start to click (assuming that they approve the buyout of Angioblast).
Melbourne, Aug 26, 2010 (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today reported its results for the year ended 30 June 2010.
With cash reserves of A$32.05 million at 30 June 2010 compared to A$16.5 million for the 2009 financial year, Mesoblast has strengthened its capacity to commercialise a broadening portfolio of its allogeneic, or "off-the-shelf", stem cell products.
The low-cost, high margin business model associated with these products is similar to pharmaceutical drugs, and underscores the company's significant commercial advantages over competitive technologies.
Mesoblast Chairman, Mr Brian Jamieson, said it had been an extremely rewarding year for Mesoblast, highlighted by the timely achievements of a number of key clinical and commercial milestones.
"A stand-out accomplishment was Mesoblast's success in obtaining a license from the Therapeutic Goods Administration (TGA) to manufacture and distribute our first generation autologous, or patient's own, adult stem cell products throughout Australia.
"This represents the first culture-expanded adult stem cell therapy that has received manufacturing approval anywhere in the world and is a strong validation of the company's science, manufacturing, preclinical and clinical strategies and results," Mr Jamieson added.
"Early adoption of our first generation products will establish a clear path for our second generation allogeneic products that are derived from a universal or unrelated donor."
Key Highlights from Clinical Trials of Allogeneic Products
- Safe and robust lumbar fusion demonstrated over 12 months in Mesoblast's first spinal fusion trial of NeoFuse (TM) at New York's Hospital for Special Surgery which employed an invasive surgical approach
- Phase 2 trials for lumbar and cervical spinal fusion products used in minimally invasive surgical procedures continue to recruit well in United States and Australia
- Phase 2 trial of RepliCart (TM) for prevention of knee cartilage loss and osteoarthritis after Anterior Cruciate Ligament damage continues recruitment in Australia
- Phase 2 trial of Revascor (TM) rdiac repair stem cell product, being developed by Mesoblast's United States associated company Angioblast Systems Inc. for congestive heart failure, has completed 60-patient recruitment; interim results indicate positive 3 and 6 month efficacy in the lowest-dose treatment group
- Angioblast's bone marrow repair product, being developed under a United States Food and Drug Administration (FDA) Orphan Drug Designation, has demonstrated successful bone marrow engraftment in 25 patients
- On the basis of the bone marrow transplantation results, Angioblast held a successful meeting with the FDA to discuss plans for moving into a Phase 3 trial; the Company remains on track to file an Investigational New Drug (IND) submission to the FDA to commence a Phase 3 trial for its bone marrow transplant product by the end of this year.
Proposed Acquisition of Angioblast
In order to maximise shareholder benefits across the entire technology platform, the Board of Directors has recommended to shareholders to consider a strategic acquisition of Angioblast. This would transform Mesoblast from a biologics company focused on orthopaedic applications to a global leader in the regenerative medicine industry. An Extraordinary General Meeting of Mesoblast shareholders to vote on the proposed acquisition is scheduled to be held on 22 September 2010.
Mr Jamieson said: "Bringing the technology platform and assets into one company would enable us to streamline corporate operations, strengthen the global leadership team, rationally allocate resources based on maximal return, and facilitate commercial partnering discussions."
Financial Summary
- Cash reserves at 30 June 2010 are A$32.05 million (2009: A$16.5 million)
- Operating cash use for the year was A$9.7 million (2009: A$9.2 million)
- Net loss for the year was A$14.8 million (2009: A$12.3 million).
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
Tel: +61-3-9639-6036
Mob: +61-419-228-128
Email: julie.meldrum@mesoblast.com
http://www.mesoblast.com
Link: http://www.abnnewswire.net/media/en/docs/63594-ASX-MSB-340887.pdf
Looks like the pump is being dumped on the news? You were doing such a good job promoting this. Insiders seemed to appreciate it. Are you averaging down?
"GET TO THE NASDAQ"... That would require these questions to be answered...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=53586860
Traders don't care if they see news that looks like it would move a stock but investors will want to know exactly where ITRO.PK stands financially before making any large long-term investments.
Looks over sold on the chart and I am already green at the closing price:) If it gets ahead of itself by being pumped up on all the boards, then just take some profit. If you do buy some even for a trade be sure to let us know because that could be the kiss of death - lol.
Good news today. I am still hoping to get accurate answers to these questions. Without knowing the break-even point for cash-flow (including debt payments) it will be impossible to know where the bottom is but it is still good to see nice progress being made on the revenue side.
Posted by: SuperSquirrel Member Level Date: Sunday, August 22, 2010 2:08:32 AM
In reply to: insidejob007 who wrote msg# 11467 Post # of 19980
As there are no filings in which to get current information and you seem to have more accurate knowledge than most on ITRO operations, can you please try to get answers to these questions?
What is the current standing with NIR and all current debts?
Do you know how much money it cost to generate the last Q's revenue? (or can you give an educated estimate at what point the process will become break even: for example 5x-7x current production which would mean that the 10x planned would actually be profitable?)
What is the dollar equivalent cost to pay the quarterly convertible debt (I know that the number of shares issued will depend on the share price at the time of the conversion)?
What is the current share structure common & preferred?
How much does DR. Whitney earn in salary from all ITRO operations (including Whitney & Whitney and any promotional speaking engagements - lol) and also how much additionally in stock compensation?
Thanks,
Why post it on any pumper boards at all? I always thought investors liked to buy as cheap as they can? It is good to see that they now have a plan and I like the stock now (at .07) much better than I did at .18 eight months ago. I still would like to know just how much of LTC shareholders will end up with.
Melbourne, Aug 23, 2010 (ABN Newswire) - Dear Shareholder
On Wednesday 22 September 2010, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) will hold an Extraordinary General Meeting of shareholders to consider a proposed acquisition of its United States-based associate company, Angioblast Systems Inc. This is a key event in your Company's evolution.
This strategic acquisition would enable Mesoblast to significantly broaden its product portfolio based on 100 per cent ownership of the intellectual property rights underpinning the entire Mesenchymal Precursor Cell (MPC) technology platform.
Fundamentally, it would transform Mesoblast from a biologics company focused on orthopaedic applications to a global leader in the regenerative medicine industry. Mesoblast shareholders would gain full commercial benefits from the breadth of applications, including cardiac, eye, diabetes and oncology.
It should be noted that the most advanced clinical programs using the proprietary "off-the-shelf" MPC adult stem cells are those conducted by Angioblast in the United States for congestive heart failure and bone marrow regeneration. The products for these conditions are therefore closest to United States Food and Drug Administration regulatory approvals and represent the nearest term and greatest revenue generating opportunities.
Bringing the technology platform and assets into one company would enable us to streamline corporate operations, strengthen the global leadership team, rationally allocate resources based on maximal return, and facilitate commercial partnering discussions. In particular, a single company with access to 100 per cent ownership of the technology platform would be greatly strengthened in its ability to establish strategic partnerships across a range of product indications.
To make an informed judgement on what the Mesoblast Board of Directors believe are fair and reasonable terms for the proposed Angioblast acquisition, we would suggest that you refer to the attached independent review of the proposed transaction conducted by Deloitte.
We are excited by the potential of this proposed acquisition to consolidate your Company's position as a global leader in the regenerative medicine industry. Your Board strongly recommends that you ratify the four resolutions that are detailed in the accompanying documents.
We look forward to seeing you at the EGM to actively endorse Mesoblast's advancement to the next critical level in its corporate maturity.
Yours sincerely
Brian Jamieson
Chairman
For the complete Mesoblast Limited Notice of Extraordinary General Meeting, please view the following link:
http://www.abnnewswire.net/media/en/docs/63574-ASX-MSB-340626.pdf
As there are no filings in which to get current information and you seem to have more accurate knowledge than most on ITRO operations, can you please try to get answers to these questions?
What is the current standing with NIR and all current debts?
Do you know how much money it cost to generate the last Q's revenue? (or can you give an educated estimate at what point the process will become break even: for example 5x-7x current production which would mean that the 10x planned would actually be profitable?)
What is the dollar equivalent cost to pay the quarterly convertible debt (I know that the number of shares issued will depend on the share price at the time of the conversion)?
What is the current share structure common & preferred?
How much does DR. Whitney earn in salary from all ITRO operations (including Whitney & Whitney and any promotional speaking engagements - lol) and also how much additionally in stock compensation?
Thanks,
I am new to this stock and to cord blood with no medical background so forgive me if I ask questions that I could find on my own but with so many stocks and so little time I'm going to start with some basics before I do any real digging.
1) Is there any convertible debt?
2) What is the current share structure (market cap).
3) Do any of the principals have a track record on operating any other public companies.
Has anyone thought about them collecting all the cord blood available in the hospitals near their facility and getting a release to own and store it with the possibility to sell it to researchers or back to family down the road (at a much greater price)? Seems like it might be worth doing at least until the facility gets close to filling up with paid private storage.
So right now, if the mother does not bank their child's cord blood then it is disposed of. Pure speculation but it seems like the lawyers will catch up with this and at some point the mother will have to sign a waiver to relinquish rights to the cord blood if she decides not to keep it? It will probably take a lawsuit where the mother needs the cord blood for her child and she was not made aware of the option to store it. If a legal release form was standard practice, then it seems like it would greatly increase awareness while indemnifying the hospital, IMHO.
I know that APNT has patents in this field, do you know if Samsung is working with APNT or is this a hypothesis?
http://asia.cnet.com/crave/2010/08/06/samsung-launching-carbon-nanotube-lcd-tvs-in-2011-/
Melbourne, Aug 16, 2010 (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided market guidance on its Phase 3 bone marrow transplant program following a formal meeting with the United States Food and Drug Administration (FDA).
For this Phase 3 program, the patented allogeneic, or "off-the-shelf", adult Mesenchymal Precursor Cells (MPCs) will be used under a United States FDA Orphan Drug Designation to expand unrelated donor haematopoietic stem and progenitor cell numbers for use in patients with haematologic malignancies.
In the meeting with the FDA, Mesoblast proposed a Phase 3 clinical trial whose design, size, duration, and primary endpoints were based on results from the 25 patient pilot trial performed at the University of Texas MD Anderson Cancer Center. Comparable control data were obtained from both MD Anderson Cancer Center and a United States registry of 300 patients collected by the Center for International Blood and Marrow Transplant Research.
The meeting was very constructive, with the FDA providing the company with expected guidance on Phase 3 primary endpoints and duration of patient follow-up. As a result of the positive meeting, and to ensure full alignment on product approval requirements, Mesoblast will seek to obtain from the FDA a binding Special Protocol Assessment (SPA) prior to commencing the Phase 3 trial. The SPA provides an agreement between the FDA and the Company regarding the design, including size and clinical endpoints, of the pivotal trial to support an efficacy claim in a Biologic License Application (BLA).
Today less than 30 per cent of individuals who could use an unrelated donor bone marrow transplant actually receive one because for the rest a fully matched donor cannot be found. Perfect matching is required because of the high risk of the potentially life-threatening complication of severe graft-versus-host disease (GVHD).
Mesoblast's objective is to make available a source of unrelated donor bone marrow cells which can be used without full matching to effect rapid bone marrow reconstitution with a low risk of GVHD. The Company believes that this would expand the use of bone marrow transplantation to all those in need of the procedure but who currently cannot find a donor.
Based on this meeting with the FDA, and in line with previous guidance, Mesoblast remains on track to file an Investigational New Drug (IND) submission to the FDA to commence a Phase 3 trial for its bone marrow transplant product by the end of this year. Mesoblast has sufficient cash reserves to fund the Phase 3 trial.
About Orphan Drug Designation
Orphan drug designation is reserved for therapies which are being developed for conditions affecting up to 200,000 patients annually in the United States, and allows for an accelerated review process by the FDA, seven-year market exclusivity in the United States upon obtaining marketing authorisation, tax benefits, and exemption from user fees.
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
Tel: +61-3-9639-6036
Mob: +61-419-228-128
Email: julie.meldrum@mesoblast.com
www.mesoblast.com
Link: http://www.abnnewswire.net/media/en/docs/63521-ASX-MSB-340206.pdf
http://abnnewswire.net/press/en/63521/Mesoblast_Limited_%28ASX:MSB%29_On_Track_For_Phase_3_Bone_Marrow_Transplant_Trial_Following_Positive_Meeting_With_United_States_Food_and_Drug_Administration_%28FDA%29.html
I don't doubt that there would be strong opposition to any direct competition but JBII is flying under the radar and will be seen as a novelty by big oil until it is too late and JBII proves to be a profitable business model and starts major expansion at which point they would have to decide to either compete or buy-out and I look forward to crossing that bridge.
While it is easy to see the potential here with ITRO, I must admit that I was under the impression that ITRO was turning the corner faster than it actually is according to my understanding of the earnings. The R/S surprise without blockbuster news was disappointing to me (along with no AS reduction). The books are so far out of date now for SEC reporting that it will take a long time and cost a lot to get them back into SEC compliance. Without full disclosure of the convertible debt an an accurate account of actual losses this could get ugly real fast unless we see some leadership with the Doc and other insiders doing some serious buying in the open market. If they have to keep diluting to pay the debt at this price level for even one or two more quarters, then it could really drive the price down. It should be a good buy when it is known for certain that they have earnings that will at least cover the convertible. IMHO
Exactly. Now here is the final word on the Pink status. AS comments on Pink
Throw me a freaking bone here. Can't believe some of the longs want to knit pick on this. NASDAQ won't even be possible until next year at least. Hey you might as well laugh, it's only money.
JBII is currently fully reporting with a reputable auditor and that does put them above 97 percent of the other OTC listed and pink stocks. Can anyone name a US pink stock that is audited by a top 50 audit firm (very few and the ones you find would not be called a scam)? I only hope that JB can produce the "goods" quickly and is learning who NOT to take advice from before it is too late. I don't want my shares to turn into a life-time supply of bend over and pack-it soaps.
BIOLASE Conference Call: 2010 Second Quarter and Six-Month Results
Date : 08/03/2010 @ 6:00AM
Source : MarketWire
Stock : BIOLASE Technology, Inc. (BLTI)
Quote : 1.05 -0.06 (-5.41%) @ 7:22AM
BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that the Company will host a conference call
on Thursday, August 12, at 11:00 a.m. Eastern Time to discuss its operating results for the second quarter and six months ended June 30, 2010, and to answer questions. The Company's results release will be distributed at approximately 6:00 a.m. Eastern Time that same day.
Phone Participation
To listen to the conference call live via telephone, please dial 1-877-941-4774 from the U.S. or, for international callers, please dial +1-480-629-9760, approximately 10 minutes before the start time.
Webcast Participation
To listen to the conference call live via the Internet, visit the Investors section of the BIOLASE website at www.biolase.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software.
Replay
An audio archive of the webcast will be available for one year on the Investors section of the BIOLASE website.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, Facebook at http://facebook.com/biolase, and YouTube at http://www.youtube.com/user/Rossca08.
For further information, please contact:
Jill Bertotti
Allen & Caron
+1-949-474-4300
Nice upward trend last few days. The "spiral death" financing is my biggest concern on ITRO and they have not been reporting on this for over a year now so if you can find out the actual debt please post it.
Averaging down here. I may have more than you now.
Thanks for the update. I added a link to the ibox for ASX quote with Bid and Offer so you can see the spread during Australian Market hours.
http://www.asx.com.au/asx/research/companyInfo.do?by=asxCode&asxCode=msb
Did you read the news about being a buyout target? I would take the bird in the hand and not complain (as if I had a choice) but really I would prefer to hold this for 10 years and see what happens.
Looks like the news was well received.
DexCom Schedules Second Quarter Earnings Release and Conference Call for August 3, 2010
Date : 07/27/2010 @ 8:30AM
Source : Business Wire
Stock : DexCom, Inc. (DXCM)
Quote : 11.93 0.13 (1.10%) @ 7:22AM
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2010 financial results after market close on Tuesday, August 3, 2010. Management will hold a conference call to review the company's second quarter 2010 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call
will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com under the investor webcast section and will be archived for future reference.
To listen to the conference call, please dial (800) 447-0521 (US/Canada) or (847) 413-3238 (International) and use the confirmation number "27580067" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.
Big Pharma Eyeing Mesoblast?
27/07/2010 3:15:02 PM
By Chris Shaw
Southern Cross Equities analyst Stuart Roberts has picked up a recent trend in the global pharmaceutical sector: an increase in merger and acquisition activity. In particular the large and medium-sized companies have been taking over smaller biotechs with promising products under development, largely as a means of re-stocking their product pipelines, says Roberts.
This trend towards deals in the sector could be significant for Mesoblast (MSB.AX)
28 July,2010
28/07/2010 04:37 Sydney, Australia.
Price Change % Change
1.860 +0.030 +1.640%
MSB.AX , 1.860, +0.030, +1.640%), as having successfully completed Phase II trials the company is now moving into Phase III trials of its Mesenchymal Precursor Cell (MPC) technology for bone marrow transplantation.
Southern Cross suggests the fact Mesoblast has some solid data behind it following the Phase II trials means there is better information available to potential acquirers. As well, the company offers a solid pipeline of stem cell applications given it is currently conducting seven Phase II trials, while it also offers long-dated patent protection out to at least 2026.
This latter point is important given Big Pharma is facing an increase in patent expiries, with a number of major drugs such as Lipitor coming off patent both this year and in 2011.
The other attraction of Mesoblast according to Southern Cross is the company's trials are helping it develop a valuable spinal franchise, as the MPC technology is being successfully applied across a spectrum of spinal related procedures. This is of value as any acquirer would therefore gain access to a large and growing segment of the orthopaedics market.
An advantage Mesoblast enjoys is the path to market in stem cell therapy is relatively short, as only one Phase II and one pivotal trial is required before approval. In the view of Southern Cross this offers scope for Mesoblast to begin earning commercial revenues as early as this year through a licensing deal with a big pharmaceutical player or medical device company.
A short development time is also important in lowering drug development costs, which are continuing to increase significantly. As Southern Cross notes, a new drug potentially costs anything from US$1.2-$1.5 billion to develop today, up from around US$800 million in the early 2000s.
Given the quick path to market the rest of 2010 should see substantial news flow for Mesoblast, which Southern Cross expects will keep investor interest in the company at elevated levels.
On Southern Cross's numbers, Mesoblast is valued at anything between $2.92 and $7.99, the lower number being its base case valuation using a probability weighted discounted cash flow approach. This has been adjusted for the company's recent capital raising and the Angioblast merger. The broker has set its price target at $3.00 in-line with this valuation.
Southern Cross rates Mesoblast as a Speculative Buy, though with a market capitalisation of less than $500 million the company doesn't receive a lot of analyst attention. The FNArena database highlights this as it shows only RBS Australia provides coverage, rating Mesoblast as a Buy with a price target of just $2.08.
Shares in Mesoblast today are higher and as at 1.50pm the stock was up 4c at $1.87. This compares to a trading range over the past year of $0.90 to $2.26 and implies upside of better than 35% to the price target of Southern Cross Equities.
Big Pharma Eyeing Mesoblast?
27/07/2010 3:15:02 PM
By Chris Shaw
Southern Cross Equities analyst Stuart Roberts has picked up a recent trend in the global pharmaceutical sector: an increase in merger and acquisition activity. In particular the large and medium-sized companies have been taking over smaller biotechs with promising products under development, largely as a means of re-stocking their product pipelines, says Roberts.
This trend towards deals in the sector could be significant for Mesoblast (MSB.AX
MESOBLAST
28 July,2010
28/07/2010 04:08 Sydney, Australia.
Price Change % Change
1.860 +0.030 +1.640%
MSB.AX , 1.860, +0.030, +1.640%), as having successfully completed Phase II trials the company is now moving into Phase III trials of its Mesenchymal Precursor Cell (MPC) technology for bone marrow transplantation.
Southern Cross suggests the fact Mesoblast has some solid data behind it following the Phase II trials means there is better information available to potential acquirers. As well, the company offers a solid pipeline of stem cell applications given it is currently conducting seven Phase II trials, while it also offers long-dated patent protection out to at least 2026.
This latter point is important given Big Pharma is facing an increase in patent expiries, with a number of major drugs such as Lipitor coming off patent both this year and in 2011.
The other attraction of Mesoblast according to Southern Cross is the company's trials are helping it develop a valuable spinal franchise, as the MPC technology is being successfully applied across a spectrum of spinal related procedures. This is of value as any acquirer would therefore gain access to a large and growing segment of the orthopaedics market.
An advantage Mesoblast enjoys is the path to market in stem cell therapy is relatively short, as only one Phase II and one pivotal trial is required before approval. In the view of Southern Cross this offers scope for Mesoblast to begin earning commercial revenues as early as this year through a licensing deal with a big pharmaceutical player or medical device company.
A short development time is also important in lowering drug development costs, which are continuing to increase significantly. As Southern Cross notes, a new drug potentially costs anything from US$1.2-$1.5 billion to develop today, up from around US$800 million in the early 2000s.
Given the quick path to market the rest of 2010 should see substantial news flow for Mesoblast, which Southern Cross expects will keep investor interest in the company at elevated levels.
On Southern Cross's numbers, Mesoblast is valued at anything between $2.92 and $7.99, the lower number being its base case valuation using a probability weighted discounted cash flow approach. This has been adjusted for the company's recent capital raising and the Angioblast merger. The broker has set its price target at $3.00 in-line with this valuation.
Southern Cross rates Mesoblast as a Speculative Buy, though with a market capitalisation of less than $500 million the company doesn't receive a lot of analyst attention. The FNArena database highlights this as it shows only RBS Australia provides coverage, rating Mesoblast as a Buy with a price target of just $2.08.
Shares in Mesoblast today are higher and as at 1.50pm the stock was up 4c at $1.87. This compares to a trading range over the past year of $0.90 to $2.26 and implies upside of better than 35% to the price target of Southern Cross Equities.
http://money.ninemsn.com.au/article.aspx?id=7935719&rf=true
Patience Friend. The stock will probably be range bound until more information is available. Just relax and wait it out. I too believe that the bottom was put in last week but now it all depends on when we get the next P2O update.
Applied Nanotech Taps Mercom Capital Group for Its Investor Relations Initiatives
Date : 07/26/2010 @ 9:15AM
Source : MarketWire
Stock : Applied Nanotech Holdings, Inc. (APNT)
Quote : 0.264 0.014 (5.60%) @ 3:50PM
Applied Nanotech Holdings, Inc. (OTCBB: APNT) is pleased to announce that it has retained Austin based Mercom Capital Group, a leading communications firm, specializing in clean energy, to provide strategic investor relations counsel and spearhead the company's investor relations outreach initiatives.
"We are confident that Mercom Capital Group is the right choice to lead our investor relations initiatives," commented Douglas Baker, CEO of Applied Nanotech. "They are highly respected in the clean energy markets and bring the expertise and a solid track record for providing strategic and highly effective communications services to companies like ours. As we enter our next stage of growth, we look forward to working with Mercom to ensure our progress is effectively communicated to the financial community. While Mercom works with companies in a variety of industries, we believe their expertise and contacts in the clean energy area fit nicely with us since many of our technologies (CarbAlâ„¢, technical inks, and nanocomposites) have applicability in this area."
"We are impressed with Applied Nanotech's ability not only to develop innovative technological solutions, but also with management's vision and leadership to take the company from R&D to a near-term commercialization phase in multiple markets. We look forward to being an integral part of their communications team and in assisting the company in achieving its business goals and objectives," commented Wendy Prabhu, President of Mercom Capital Group.
About Applied Nanotech Holdings
Applied Nanotech Holdings, Inc. is a premier research and commercialization organization focused on solving problems at the molecular level. Its team of PhD level scientists and engineers work with companies and other organizations to solve technical impasses and create innovations that will create a competitive advantage. The business model is to license patents and technology to partners that will manufacture and distribute products using the technology. Applied Nanotech has over 250 patents or patents pending. For more information about APNT, visit: http://www.appliednanotech.net.
About Mercom Capital Group
Mercom Capital Group is a clean energy communications and consulting firm with offices in the US and India. Mercom's communications division helps companies build powerful relationships with media, analysts, investors, government decision-makers, local communities and strategic partners. Mercom's consulting division advises companies on new market entry, custom market intelligence and overall strategic decision-making. Mercom's highly respected industry market intelligence reports provide timely industry happenings and ahead-of-the-curve analysis to a large network of clean energy industry executives, funding groups, government agencies, analysts, media and more. For more information about Mercom Capital Group, visit: http://www.mercomcapital.com. To get a copy of Mercom's popular market intelligence reports, visit: http://mercomcapital.com/market_intelligence.php.
Safe Harbor Statement
This release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report on Form 10-K for the fiscal year ended December 31, 2009, and in reports subsequently filed by us with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at www.sec.gov or from our website listed above. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.
Company Contact:
Doug Baker
Applied Nanotech Holdings, Inc.
Tel: 1.248.391.0612
E-mail: Email Contact
Mercom Capital Group
Wendy Prabhu
Tel: 1.512.215.4452
E-mail: Email Contact
I am aware of every point you are trying to make but it does not seem like you are aware that JB stated he would not be using his super voting preferred shares for the votes at the last AGM.
A true valuation of JBI Global is impossible until the actual efficiencies of the P2O process is known so anyone buying is speculating that the process will be at least economically feasible enough to get JV's interested. It is highly speculative and if efficiencies prove to be considerably better and cheaper than competitors, then that speculation will be rewarded eventually. If the process is not economically feasible, then JBI is very over valued.
Because it will not be needed for a year or two and it is taking up time and resources now besides the association issues. If JB had waited until after P2O has been proven to the market, then they could have used much less stock to purchase JAVACO and we would not be talking about Kidd's shares as they will not matter as long as P2O is proven to be an efficient, profitable operation.